At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 254 enrolled
Drug / intervention
Suvorexant +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIb, Multicenter, Randomized, Double-Blind Placebo-Controlled, 2-period Adaptive Crossover Polysomnography Study to Evaluate Safety and Efficacy of MK-4305 in Patients With Primary Insomnia
In Brief
A Phase 2 clinical trial evaluating Suvorexant and Dose-matched Placebo to Suvorexant for Primary Insomnia. Completed, enrolled 254 participants.
Detailed Summary
A cross-over, polysomnography study to test the safety, tolerability and effectiveness of different doses of suvorexant (MK-4305) in the treatment of patients with primary insomnia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Insomnia
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2008
First PostedNov 2008
Primary CompletionDec 2009
TodayJul 2026
First PostedNov 17, 2008
Enrollment StartNov 5, 2008
Primary CompletionDec 26, 2009
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 17.6 years ago
Interventions
Suvorexantdrug
oral tablet taken before bedtime
Dose-matched Placebo to Suvorexantdrug
Dose-matched placebo to suvorexant taken before bedtime (oral tablet)